Literature DB >> 11379874

Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling.

C Le Maréchal1, M P Audrézet, I Quéré, O Raguénès, S Langonné, C Férec.   

Abstract

More than 900 mutations and more than 200 different polymorphisms have now been reported in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ten years after the cloning of the CFTR gene, the complete scanning of the 27 exons to identify known and novel mutations remains challenging. Rapid accurate identification of mutated alleles is important for prenatal diagnosis, for cascade screening in families at risk of cystic fibrosis (CF) and for understanding the correlation between genotype and phenotype. In this study, we report the successful use of denaturing ion-pair reverse-phase high performance liquid chromatography (D-HPLC) to analyse rapidly the complete coding sequence of the CFTR gene. With 27 pairs of polymerase chain reaction primers, we optimised the temperature conditions required for the analysis of each amplicon and validated thetest conditions on samples from a panel of 1552 CF patients who came from France and other European countries and who had mutations and polymorphisms located in the various melting domains of the gene. D-HPLC identified 415 mutated alleles previously characterised by denaturing gradient gel electrophoresis and DNA sequencing, plus 74 novel mutations reported here. This new technique for screening DNA for sequence variation was extremely accurate (it identified 100% of the CFTR alleles tested so far) and rapid (the complete CFTR gene could be analysed in less than a week). Our approach should reduce the number of untyped CF alleles in populations and thus decrease the residual risk in couples at risk of CF. This technique may be important not only for CF,but also for many other genes with a high frequency of point mutations at a variety of sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11379874     DOI: 10.1007/s004390100490

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

1.  Notable contribution of large CFTR gene rearrangements to the diagnosis of cystic fibrosis in fetuses with bowel anomalies.

Authors:  Alix de Becdelièvre; Catherine Costa; Annick LeFloch; Marie Legendre; Jean-Marie Jouannic; Jacqueline Vigneron; Jean-Luc Bresson; Stéphanie Gobin; Josiane Martin; Michel Goossens; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2010-05-26       Impact factor: 4.246

2.  A new insertion/deletion of the cystic fibrosis transmembrane conductance regulator gene accounts for 3.4% of cystic fibrosis mutations in Sardinia: implications for population screening.

Authors:  Valeria Faà; Pietro Pellegrini Bettoli; Maria Demurtas; Maurizio Zanda; Vincenzina Ferri; Antonio Cao; Maria Cristina Rosatelli
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

3.  A haplotype framework for cystic fibrosis mutations in Iran.

Authors:  Elahe Elahi; Ahmad Khodadad; Ilya Kupershmidt; Fereshteh Ghasemi; Babak Alinasab; Ramin Naghizadeh; Robert G Eason; Mahshid Amini; Mehran Esmaili; Mohammad R Esmaeili Dooki; Mohammad H Sanati; Ronald W Davis; Mostafa Ronaghi; Yvonne R Thorstenson
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Functional analysis of synonymous substitutions predicted to affect splicing of the CFTR gene.

Authors:  Alexandra Scott; Hanna M Petrykowska; Timothy Hefferon; Valer Gotea; Laura Elnitski
Journal:  J Cyst Fibros       Date:  2012-05-14       Impact factor: 5.482

5.  New frameshift CF mutation 3729delAinsTCT in a Tunisian cystic fibrosis patient.

Authors:  Sondess Hadj Fredj; Monia Boudaya; Sabrine Oueslati; Safa Sahnoun; Chaima Sahli; Hajer Siala; Khedija Boussetta; Amina Bibi; Taieb Messaoud
Journal:  J Genet       Date:  2013-04       Impact factor: 1.166

6.  The use of DHPLC (Denaturing High Performance Liquid Chromatography) in II level screening of the CFTR gene in Prenatal Diagnosis.

Authors:  Alvaro Mesoraca; Manuela Di Natale; Antonella Cima; Gianluca Di Giacomo; Monica Sarti; Maria Antonietta Barone; Domenico Bizzoco; Pietro Cignini; Luisa Mobili; Laura Dʼemidio; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2010-07

7.  Prenatal screening of Cystic Fibrosis: a single centre experience.

Authors:  Domenico Bizzoco; Alvaro Mesoraca; Antonella Cima; Monica Sarti; Gianluca Di Giacomo; Giovanna Scerra; Maria Antonietta Barone; Manuela Di Natale; Ivan Gabrielli; Caterina Tamburino; Claudia Scargiali; Cristina Ernandez; Maria Pia D'Aleo; Michele Todini; Rita Pompili; Luisa Mobili; Lucia Mangiafico; Ornella Carcioppolo; Claudio Coco; Pietro Cignini; Laura D'Emidio; Alessandra Girgenti; Cristiana Brizzi; Alessandro Cavaliere; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2008-01

8.  Complete ascertainment of intragenic copy number mutations (CNMs) in the CFTR gene and its implications for CNM formation at other autosomal loci.

Authors:  Sylvia Quemener; Jian-Min Chen; Nadia Chuzhanova; Caroline Bénech; Teresa Casals; Milan Macek; Thierry Bienvenu; Trudi McDevitt; Philip M Farrell; Ourida Loumi; Taieb Messaoud; Harry Cuppens; Garry R Cutting; Peter D Stenson; Karine Giteau; Marie-Pierre Audrézet; David N Cooper; Claude Férec
Journal:  Hum Mutat       Date:  2010-04       Impact factor: 4.878

9.  Influence of the duplication of CFTR exon 9 and its flanking sequences on diagnosis of cystic fibrosis mutations.

Authors:  Ayman El-Seedy; Tony Dudognon; Frédéric Bilan; Marie-Claude Pasquet; Marie-Pierre Reboul; Albert Iron; Alain Kitzis; Véronique Ladeveze
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

10.  Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening.

Authors:  Aimee C Walsh; Gilles Rault; Zhanhai Li; Virginie Scotet; Ingrid Duguépéroux; Claude Férec; Michel Roussey; Anita Laxova; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2009-11-18       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.